Quininib

Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents[1].

Product Specifications

CAS Number

[143816-42-6]

UNSPSC

12352005

Target

Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/quininib.html

Purity

98.1

Solubility

10 mM in DMSO

Smiles

OC1=CC=CC=C1/C=C/C2=NC3=CC=CC=C3C=C2

Molecular Formula

C17H13NO

Molecular Weight

247.29

References & Citations

[1]Alison L Reynolds, et al. Phenotype-based Discovery of 2-[ (E) -2- (Quinolin-2-yl) vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem. 2016 Apr 1;291 (14) :7242-55.